NCT00506441: A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia

Sponsor: Tanabe Pharma Corporation. Phase: PHASE3. Conditions: Chronic Kidney Disease, Dialysis, Hyperphosphatemia